AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Talphera, Inc. (TLPH) reported Q3 2025 earnings, with a focus on continued enrollment in the NEPHRO clinical study and a financing completion. The company also highlighted progress in its clinical study sites and a financing completion. Talphera's CFO, Raffi Asadorian, and CEO, Vincent Angotti, were joined by Chief Medical Officer Shakil Aslam on the earnings call.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet